Ruyi He， MD.  Adjunct Professor, Director of Academic Committee, Center for Regulatory Science, School of Medicine , Tsinghua University; Chief Medical Officer, SDIC Fund Management Co

Dr. Ruyi He was the Chief Scientist at the Center for Drug Evaluation at the Chinese Food and Drug Administration (CFDA). He organized and participated the recent reform of Chinese drug review system. Dr. He joined CFDA in July 2016, after having worked at the US Food and Drug Administration (FDA) for more than 17 years.

Dr. Ruyi He joined the US Center for Drug Evaluation and Research (CDER) at the US FDA in 1999 as a Medical Officer in the office of New Drug. He chaired several working groups that were tasked with drafting and finalizing guidelines for industry, and was also involved in FDA guidance development in multiple therapeutic areas. He was responsible for approving numerous applications for investigational new drugs (INDs) and new drug applications (NDAs). Dr. Ruyi He has received many awards since he joined the FDA, including the FDA Excellence in Review Science Award, CDER Leadership Excellence Award, CDER Excellence in Mentoring Award, FDA Award of Merit, and the Department of Health and Human Services Secretary’s Award for Distinguished Service.

Dr. Ruyi He received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. He received his clinical and research training at the National Institutes of Health (NIH) in Bethesda, Maryland. He is a licensed, board-certified physician in several States in the America.